Indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D and to reduce risk of major adverse CV events (MACE=CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with T2D and established CVD. Scroll below for Limitations of Use.
Meet Lisa's guests
These providers come from a range of specialties and clinical environments. But they have one thing in common: they see Ozempic® as an appropriate choice for patients with type 2 diabetes who are ready for intensification of therapy.
Dr Carolina Solis-Herrera
Endocrinologist and Assistant Professor of Medicine
UT Health, San Antonio, TX
Dr Jennifer Goldman
Clinical pharmacist, CDCES, BC-ADM, FCCP
Massachusetts College of Pharmacy and Health Sciences, Boston, MA
I’m a strong believer in Ozempic® for appropriate patients with T2D, and I hope this series will show you why.
Watch full episodes from the series
Watch the To-Go versions
Listen to the podcasts
Why I Prescribe Ozempic®
with Dr Carolina Solis-Herrera
Duration: 20:19
Released: 02/25/2022
Lisa and Dr Solis-Herrera talk T2D treatment algorithms, the SUSTAIN 7 study, and how their patients feel about injectable therapies.
When I'm teaching or speaking at a conference, the SUSTAIN 7 results are always an aha moment for the audience.
Duration: 20:19
Released: 02/25/2022
Lisa and Dr Solis-Herrera talk T2D treatment algorithms, the SUSTAIN 7 study, and how their patients feel about injectable therapies.
When I'm teaching or speaking at a conference, the SUSTAIN 7 results are always an aha moment for the audience.
Approaches to Injectable Therapy
with Dr James R. Gavin III
Duration: 23:35
Released: 02/25/2022
Lisa and Dr Gavin discuss the issue of clinical inertia in T2D treatment, and what the SUSTAIN 4 and SUSTAIN 5 studies say about Ozempic® and basal insulin.
We need to break the cycle of clinical inertia in the intensification of therapy for our patients with type 2 diabetes.
Duration: 23:35
Released: 02/25/2022
Lisa and Dr Gavin discuss the issue of clinical inertia in T2D treatment, and what the SUSTAIN 4 and SUSTAIN 5 studies say about Ozempic® and basal insulin.
We need to break the cycle of clinical inertia in the intensification of therapy for our patients with type 2 diabetes.
The Role of Ozempic® in Cardiology
with Dr Joshua M. Stolker
Duration: 20:16
Released: 02/25/2022
Lisa and Dr Stolker discuss how and why he prescribes Ozempic® and his advice for others in cardiology who see patients with T2D and established cardiovascular disease.
I used to work with an appropriate patient’s PCP or endocrinologist to start them on a GLP-1 RA like Ozempic®. But now, I prescribe Ozempic® myself.
How Patient Support Can Help
with Dr Jennifer Goldman
Duration: 20:49
Released: 02/25/2022
Lisa and Dr Goldman compare their notes on how type 2 diabetes care has changed over time and what providers can do to help patients get off to a good start with Ozempic®.
Patients may think they’ll remember everything we talked about at a visit, but it’s great to have something to take home that also captures some of that.
Duration: 20:49
Released: 02/25/2022
Lisa and Dr Goldman compare their notes on how type 2 diabetes care has changed over time and what providers can do to help patients get off to a good start with Ozempic®.
Patients may think they’ll remember everything we talked about at a visit, but it’s great to have something to take home that also captures some of that.
(24:33)
(27:54)
(24:51)
(21:43)
Copy this address into your favorite podcast player:
http://coffeewithcoco.novomedlink.com/
Copy this address into your favorite podcast player:
http://coffeewithcoco.novomedlink.com/
Thanks for joining us! I hope these discussions have given you a fresh perspective on Ozempic® for appropriate patients with T2D.
Want to know more about starting your appropriate patients on Ozempic®?
Looking for more about the topics covered on Coffee with Coco?
Looking for more about the topics covered here?
Efficacy data from
SUSTAIN 7, 4, and 5
Ozempic® and weight
Ozempic® is not indicated for weight loss.
SUSTAIN 6 CVOT
Patient resources
Important Safety Information for Ozempic® (semaglutide) injection
WARNING: RISK OF THYROID C-CELL TUMORS
- In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Ozempic® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
- Ozempic® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Ozempic® and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Ozempic®.
Indications and Limitations of Use
Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes mellitus and established CV disease.
- Ozempic® has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
- Ozempic® is not indicated for use in patients with type 1 diabetes mellitus.
Important Safety Information cont.
Contraindications
- Ozempic® is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a hypersensitivity reaction to semaglutide or to any of the excipients in Ozempic®. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with Ozempic®.
Warnings and Precautions
- Risk of Thyroid C-Cell Tumors: Patients should be referred to an endocrinologist for further evaluation if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging.
- Pancreatitis: Acute and chronic pancreatitis have been reported in clinical studies. Observe patients carefully for signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting). If pancreatitis is suspected, discontinue Ozempic® promptly, and if pancreatitis is confirmed, do not restart.
- Diabetic Retinopathy Complications: In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with Ozempic® (3.0%) compared with placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline than among patients without a known history of diabetic retinopathy.
Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. The effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been studied. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy. - Never Share an Ozempic® Pen Between Patients: Ozempic® pens must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens.
- Hypoglycemia: Patients receiving Ozempic® in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
- Acute Kidney Injury: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists. Some of these events have been reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of Ozempic® in patients reporting severe adverse gastrointestinal reactions.
- Hypersensitivity: Serious hypersensitivity reactions (eg, anaphylaxis, angioedema) have been reported in patients treated with Ozempic®. If hypersensitivity reactions occur, discontinue use of Ozempic®; treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist.
- Acute Gallbladder Disease: Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients treated with Ozempic® 0.5 mg and 1 mg, respectively, and not reported in placebo-treated patients. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.
Adverse Reactions
- The most common adverse reactions, reported in ≥5% of patients treated with Ozempic® are nausea, vomiting, diarrhea, abdominal pain, and constipation.
Drug Interactions
- When initiating Ozempic®, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia.
- Ozempic® causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications, so caution should be exercised.
Use in Specific Populations
- There are limited data with semaglutide use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. Discontinue Ozempic® in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide.
Please click here for Ozempic® Prescribing Information, including Boxed Warning.